&w=3840&q=100)
World Ovarian Cancer Day 2025: Symptoms, risks, and how to protect yourself
Ovarian cancer, often termed the 'silent killer,' is notorious for its subtle and sneaky symptoms and late-stage diagnoses. Many women tend to overlook the symptoms, often mistaking them for common issues like bloating, hormonal fluctuations, or everyday fatigue. And so, it remains one of the most challenging gynaecological cancers worldwide. On this World Ovarian Cancer Day, May 8, know the signs and symptoms of ovarian cancer before it's too late.
What is ovarian cancer?
Ovarian cancer occurs when abnormal cells in the ovaries (organs that produce eggs) or fallopian tubes (channels connecting the ovaries to the uterus) begin to grow, mutate, and multiply uncontrollably, potentially forming tumours and spreading to other parts of the body.
Who is at risk of developing ovarian cancer?
According to the American Cancer Society, a leading cancer-fighting and research organisation, ovarian cancer affects women, especially those over 50, with most cases occurring after menopause. It is rare in women younger than 40. Women with a strong family history of breast or ovarian cancer are at a significantly higher risk.
Inherited mutations in BReast CAncer 1 or 2 (BRCA1 or BRCA2) genes, as well as other genetic conditions like Lynch syndrome, are major risk factors, according to MedlinePlus, a body of the US health and human services department.
Cleveland Clinic, a nonprofit academic medical centre based in Cleveland, Ohio, US, says that ovarian cancer is slightly more common in white women than in other racial groups.
Being overweight, smoking, and having certain medical conditions like diabetes can also increase the risk, says the Centers for Disease Control and Prevention (CDC), the national public health agency of the US.
How prevalent is ovarian cancer worldwide and in India?
Ovarian cancer is the eighth most common cancer among women all over the world, and the lifetime risk of developing ovarian cancer is approximately 1 in 78, according to a January 2025 paper published in the peer-reviewed journal eClinicalMedicine.
According to World Cancer Research Fund, globally, ovarian cancer is the 18th most common cancer and the 8th most common in women. In 2022, there were 324,603 new cases.
A study published in the Journal of Cancer Research and Therapeutics, a publication of Association of Radiation Oncologists of India, said that in India, the incidence rate of ovarian cancer is 5.08 per 100,000 women.
Signs and symptoms of ovarian cancer to watch for
Early detection is crucial, yet challenging due to nonspecific symptoms. Key warning signs include:
Persistent bloating
Pelvic or abdominal pain
Difficulty eating or feeling full quickly
Frequent or urgent urination
Fatigue
Back pain
Changes in bowel habits
Unexplained weight loss
If these symptoms occur frequently, it's essential to consult a healthcare professional.
Prevention and lifestyle changes to reduce risk
While there's no guaranteed way to prevent ovarian cancer, experts recommend certain measures to reduce risk:
Why World Ovarian Cancer Day is significant
May 8 was established as World Ovarian Cancer Day in 2013 by a group of leaders from ovarian cancer advocacy organisations around the world, led by the World Ovarian Cancer Coalition.
The day aims to raise awareness on the early signs, risk factors, and the importance of early detection, which can significantly improve survival rates. It mobilises healthcare professionals, policymakers, and communities to improve access to screening, research, and treatment.
Theme of World Ovarian Cancer Day 2025: 'No woman left behind'
The theme of this year is 'No woman left behind'—focusing on educating people about ovarian cancer globally, especially in countries that are underdeveloped and underserved, and enabling the reach of effective screening and treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
7 hours ago
- Time of India
This common UAE summer effect could be worsening your health; doctors explain
As summer temperatures soar across the UAE, doctors are warning that extreme heat can trigger underlying health conditions and worsen symptoms in vulnerable individuals, particularly those with chronic neurological and cardiovascular diseases. While most people associate high temperatures with heat stroke and dehydration, medical experts say the impact goes deeper, often unmasking or aggravating dormant conditions. Among the most affected are patients with Multiple Sclerosis (MS), a neurological disorder that impacts the central nervous system. What is Multiple Sclerosis? Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (brain, spinal cord, and optic nerves) by damaging the protective myelin sheath surrounding nerve fibers. This damage disrupts nerve signal transmission, leading to symptoms such as muscle weakness, numbness, vision problems, difficulty walking, coordination issues, fatigue, and cognitive impairments. Live Events 'Between 60 and 80 percent of people with MS report a worsening of symptoms such as fatigue, mobility issues, and visual disturbances during hot weather,' said Professor Anu Jacob, Director of Multiple Sclerosis and Autoimmune Neurology at Cleveland Clinic Abu Dhabi, as told to Khaleej Times. This temporary flare-up, known as Uhthoff's phenomenon, occurs when a rise in body temperature affects damaged nerves. Symptoms generally subside with rest and cooling. Jacob said hydration, cooling vests, and avoiding peak outdoor hours are key to symptom management. He also noted the UAE's efforts in building accessible, shaded, and air-conditioned public spaces, which are crucial for people with chronic conditions. According to a report by Khaleej Times, to move toward accessibility, the National MS Society has introduced the Universal Design for Inclusion Programme, partnering with six UAE universities to foster student-led innovations in inclusive infrastructure. Warning signs of severe heat-related illness include confusion, fainting, rapid heart rate, and cessation of sweating, which may require medical attention. Doctors stress that early intervention and preventive care are essential for at-risk groups. Economic Times WhatsApp channel )
&w=3840&q=100)
First Post
11 hours ago
- First Post
Doctor explains: Why appendix cancer is rising among the young and how it differs from colon cancer
Appendix cancer, once rare, is now rising sharply among younger people. Firstpost brings out an expert's views on the risk factors, symptoms and why early detection remains a challenge. read more Once considered extremely rare, appendix cancer is now showing a worrying rise particularly among younger adults. New research suggests that cases have quadrupled in recent decades with many detected at advanced stages due to vague or absent symptoms. As awareness remains low and early detection difficult, understanding the signs, risk factors and treatment pathways becomes critical. Firstpost spoke to Dr Amit Javed, Senior Director – GI & GI Oncology, Fortis Hospital (Gurugram) to understand why appendix cancer is on the rise, how it presents clinically and what can be done to improve outcomes. Why are appendix cancer cases rising among younger adults, particularly millennials and Gen Z? Dr Amit: While appendiceal cancer remains a relatively rare malignancy, there has been a noticeable increase in diagnoses among younger adults in recent years. This trend, similar to what has been observed in early-onset colorectal cancers, may be attributed to a combination of improved diagnostic capabilities and changing risk factors. Advanced imaging techniques, greater use of diagnostic laparoscopy, and more frequent appendectomies for non-specific abdominal pain have likely led to increased incidental detection of early-stage appendiceal tumors. However, this alone may not fully explain the shift in age demographics. Emerging research suggests that shifts in gut microbiota, rising obesity rates, dietary patterns rich in processed foods, sedentary lifestyles, and possible environmental exposures may be influencing cancer biology in younger cohorts. More data is needed to conclusively identify causative links, but the trend is certainly being observed across high-resource healthcare settings. Is there a known link between appendix cancer and lifestyle, genetics or environmental exposures in younger populations? Dr Amit: Currently, there is no single established cause of appendix cancer. However, certain associations are being actively studied: •Lifestyle Factors: Diets high in red or processed meats, low fibre intake, and obesity known contributors to colorectal cancer may also play a role in appendix malignancies, though data is limited. •Environmental Exposures: Exposure to microplastics, industrial chemicals, and endocrine-disrupting substances may influence carcinogenesis in the gastrointestinal tract, including the appendix. However, this is still an area of ongoing investigation. •Genetic Predisposition: Some appendiceal tumours may be associated with Lynch syndrome or familial cancer syndromes, though far less commonly than colorectal cancer. Molecular profiling is now recommended in many cases to evaluate for potential hereditary links. In most young patients, appendix cancer appears sporadic, but the rising numbers point toward the need for deeper evaluation of modern environmental and epigenetic influences. Given that appendix cancer is often detected late due to vague symptoms, what early signs should individuals especially young adults watch out for? Dr Amit: Appendix cancer often presents with non-specific symptoms, making early detection challenging. In younger adults, the following signs should prompt medical evaluation: •Persistent or recurrent right lower abdominal pain, especially if similar to appendicitis but not resolving •Unexplained abdominal bloating or distension •Altered bowel habits without an identifiable cause •Unintended weight loss, fatigue, or anemia •A palpable mass or fullness in the lower abdomen In many cases, appendiceal tumours are incidentally discovered during appendectomy for presumed acute appendicitis. This underlines the importance of histopathological analysis of every appendectomy specimen, even in young patients. How is appendix cancer different, genetically and clinically from other gastrointestinal cancers such as colon or rectal cancer? Dr Amit: Appendix cancer is a biologically and clinically distinct entity from colorectal malignancies. It encompasses several histologic subtypes, including: •Neuroendocrine tumours (NETs) •Mucinous adenocarcinomas •Goblet cell carcinoids •Signet ring cell carcinomas Each of these has unique behaviour, prognosis, and treatment pathways. Genetically, appendix tumours may harbour different molecular signatures, including variations in KRAS, GNAS, and TP53 mutations, particularly in mucinous tumours. Unlike colorectal cancers, microsatellite instability (MSI) and APC mutations are less common. Clinically, mucinous tumours can produce large amounts of mucin, sometimes leading to pseudomyxoma peritonei (PMP) — a condition rarely seen in other GI cancers. Treatment and surveillance strategies are therefore quite different. Can you walk us through how appendix cancer is typically diagnosed and staged? Are there improvements in imaging or biomarkers that aid in earlier detection? Dr Amit: Diagnosis often begins incidentally during surgery for suspected appendicitis. If a tumour is suspected pre-operatively, the following steps are involved: Imaging: •Contrast-enhanced CT scans remain the mainstay for detecting masses, mucinous ascites, or peritoneal spread. •MRI with diffusion-weighted imaging is increasingly used, particularly for mucinous tumours, to better characterise peritoneal involvement. •PET-CT may be helpful in certain subtypes, especially aggressive variants or high-grade neuroendocrine tumours. Tumour Markers: •CEA, CA 19-9, and CA-125 may be elevated in mucinous appendiceal cancers, although they are not diagnostic and are mainly used for monitoring. •Histopathology and Immunohistochemistry: •Once the appendix is removed, detailed pathological examination is essential to classify the tumour type, grade, and margins. Staging: •Staging follows the AJCC TNM system, but peritoneal cancer index (PCI) scoring is also critical in cases involving peritoneal spread to guide surgical decision-making. While no single biomarker currently allows for early non-invasive detection, research is ongoing into liquid biopsy and circulating tumour DNA (ctDNA) for earlier diagnosis and monitoring. What are the current treatment options available for appendix cancer? How effective are newer approaches like HIPEC (Hyperthermic Intraperitoneal Chemotherapy)? Dr Amit: Treatment depends heavily on the tumour histology, grade, and extent of spread: •Localised tumours (e.g., small neuroendocrine tumours <2 cm) may be treated with appendectomy alone. •Larger or invasive tumours typically require a right hemicolectomy to ensure adequate lymph node clearance. •Mucinous tumours with peritoneal dissemination or PMP are managed with: •Cytoreductive surgery (CRS) — complete surgical removal of visible tumour •Followed by HIPEC — heated chemotherapy circulated in the abdomen to target microscopic residual disease HIPEC has revolutionized survival outcomes in selected patients with peritoneal spread, offering long-term survival and in some cases, cure particularly when performed in high-volume centers with surgical expertise. •Systemic chemotherapy is used selectively in high-grade tumours or inoperable cases, often with regimens similar to colorectal cancer. Do you see a need for changes in screening guidelines or increased awareness in primary care to address this rise in younger patients? Dr Amit: Given the rarity and variable presentation of appendix cancer, routine population-based screening is not currently recommended. However, there is a growing need for: •Greater awareness among primary care physicians and emergency practitioners to consider malignancy in atypical or recurrent abdominal pain, especially in younger patients •Routine histopathological examination of all appendectomy specimens, regardless of patient age •Genetic counselling and testing in young patients with aggressive or familial patterns of disease •Investment in biobanking and molecular profiling to better understand early-onset GI cancers, including appendiceal tumours As trends evolve, surveillance strategies may eventually be tailored for higher-risk populations, especially if environmental or genetic risk markers are identified in the future.
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Genomic testing sees sharp uptake in India, now growing beyond metros
With 18 per cent CAGR, India's genomic diagnostics market is expanding into Tier 2 and 3 cities as affordability, cancer screening, and personalised care fuel adoption Anjali Singh Mumbai Demand for genomic testing in India has surged significantly over the past two to three years, fuelled by growing clinical awareness, rapid technological advancements and the rising adoption of personalised medicine. From being a niche service concentrated in major metros, genomic diagnostics are now expanding into Tier 2 and Tier 3 cities, reshaping the landscape of preventive and precision healthcare. The Indian genomic diagnostics market is valued at $550 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 18 per cent, reaching $2,066.31 million by 2030, according to industry estimates. Key drivers include wider physician adoption, declining test prices, improved accessibility and a shift in consumer behaviour towards proactive and personalised healthcare. Diagnostic majors such as Agilus Diagnostics, Metropolis Healthcare, Dr Lal PathLabs, Mahajan Imaging and Labs, and Redcliffe Labs report double-digit growth in the segment. While metros like Mumbai, Bengaluru and Delhi still contribute the lion's share, growing awareness and infrastructure in cities like Lucknow, Bhubaneswar, Pune, Kochi and Surat are driving demand beyond urban hubs. Test affordability has improved substantially. Prices for routine genomic tests—like BRCA1/2 (used to analyse a person's DNA to identify mutations in genes that increase the risk of breast and ovarian cancer) and NIPT (non-invasive prenatal testing, a blood test performed on pregnant women to assess the risk of certain genetic conditions in the foetus)—have come down by 30–40 per cent, now ranging between Rs 5,000 and Rs 20,000, depending on complexity. While advanced oncology panels and exome sequencing can still cost up to Rs 2 lakh, widespread adoption of high-throughput platforms and in-house test development has made even complex testing more accessible. Experts believe that although demand for genomic testing is rising across multiple segments, increasing cancer incidence and a countrywide focus on cancer detection and reproductive health have been key growth drivers. 'The rapid increase in demand for cancer tests, along with paediatric and reproductive health applications like prenatal testing and carrier testing, are major contributing factors driving growth in genetic testing. The country is also witnessing a rise in testing for rare genetic diseases, driven by India's huge genetic diversity,' said Nilaya Varma, group chief executive officer and co-founder, Primus Partners. 'Genomic testing now contributes 5–7 per cent of our total diagnostics revenue, up from under 2 per cent three years ago,' said Anand K, managing director and chief executive officer, Agilus Diagnostics. Redcliffe Labs pegs this number even higher, at 30–40 per cent, with consistent 20 per cent year-on-year growth in test volumes. 'We've seen a dramatic rise in genomic testing demand over the past five years, especially in oncology, rare diseases and reproductive health. What's encouraging is that Tier 2 and 3 cities like Lucknow, Bhubaneswar and Coimbatore are now actively adopting these tests,' said Himani Pandey, lab head – genomics, Redcliffe Labs. Metropolis Healthcare, which entered the genomics space three years ago, has seen over 50 per cent revenue growth in the segment and plans further expansion through investments in bioinformatics and next-generation sequencing (NGS) platforms. 'We've seen over 50 per cent revenue growth in genomics since our entry into the space three years ago. Genomic testing is increasingly being integrated into routine health check-ups, cancer diagnostics, rare disease screening and personalised treatment planning. We are investing heavily in bioinformatics and NGS platforms to scale further,' said Kirti Chadha, chief scientific and innovation officer, Metropolis Healthcare. Similarly, Dr Lal PathLabs, through its genomics division Genevolve, has launched over 500 tests covering oncogenomics, neurogenomics, rare disease panels and reproductive health. 'With Illumina's NovaSeq X platform at our national reference lab and a focused genomics sales team, we're bringing cutting-edge testing to both metros and smaller towns,' said Shankha Banerjee, chief executive officer, Dr Lal PathLabs. While margins on genomic tests can vary—and in many cases remain lower than routine diagnostics due to high input costs and low volumes—players see genomics as a long-term strategic bet. 'It's not just about margins—it's about clinical value and helping doctors make better treatment decisions,' said Shelly Mahajan, lab director at Mahajan Imaging. A common thread across players is the push for in-house development and Indian population–specific panels, often coupled with global partnerships for specialised tests. Most labs are also investing in AI-driven bioinformatics, advanced molecular labs and automation to enhance scalability. Yet, challenges remain. Despite cost reductions, insurance coverage for genomic tests in India is still extremely limited, creating affordability barriers for patients in lower-income segments. Industry leaders stress that broader insurance inclusion could accelerate adoption, particularly for cancer, rare diseases and reproductive health-related tests. Nonetheless, the momentum is clear: Genomic testing is no longer a fringe offering. With its ability to provide deep molecular insights for early diagnosis, targeted therapy and risk prediction, it is fast becoming a core pillar in India's diagnostics growth strategy.
